BKC wrote: "Please also note that the question of compliance was raised when the discussant at AHA mentioned the better performance of Apabetalone in the low LDL population relative to the high LDL population."

BKC or anyone else. For the subgroup analyses on slide 19 for above and below LDL-C and HbA1c, is this based on baseline values at start of study or values at end of study

Similar question for the eGFR<60 vs. eGFR>60. eGFR at baseline or end of study?

BDAZ